【摘要】：目的:通過Meta分析評價丙泊酚對肝臟缺血再灌注損傷的保護作用。 方法:按照制定的檢索策略系統(tǒng)檢索Pub Med、EMBASE、Web of Knowledge、TheCochane Library、中國生物醫(yī)學文獻數(shù)據(jù)庫、萬方全文數(shù)據(jù)庫、維普中文科技期刊數(shù)據(jù)庫、中國知網(wǎng)，檢索日期截止到2014年2月28日，限中英文語種，并計算機或手工查閱研究中引用的參考文獻。按照制定的納入和排除標準，納入所有研究丙泊酚麻醉對肝門阻斷的肝臟切除術成年病人的肝缺血再灌注影響的隨機對照試驗，對獲得2篇以上相關的全文文獻應用RevMan5.2軟件進行Meta分析。 結果:共檢索到21篇符合納入標準的文獻，共計1097例病例，其中試驗組686例，對照組511例。主要的結局指標：肝門阻斷末到再開放15min(T1) SOD、MDA、ALT、AST，肝門再開放30-45min(T2) SOD、MDA。術后第1天(T3) ALT、AST，術后第3-4天(T4) ALT、AST。Meta分析結果如下，T1SOD：MD為15.08nU/ml，95%CI為(10.81,19.36) nmol/l，P0.05；T2SOD：MD為24.20nU/ml，95%CI為(17.86,30.53) nmol/l，P0.05；T1MDA：MD為-5.73nmol/l，95%CI為(-7.29,-4.16) nmol/l，P0.05；T2MDA：MD為-5.81nmol/l，95%CI為(-7.84，-2.71) nmol/l，P0.05；T1ALT：MD為-24.46IU/L，95%CI為(-30.86,-18.04)IU/L，P0.05；T3ALT：MD為-31.49IU/L，95%CI為(-36.73,-26.26) IU/L，P0.05；T4ALT：MD為-0.77IU/L，95%CI為(-2.63,1.10) IU/L，P=0.42；T1AST:MD為-23.85IU/L，95%CI為(-29.78,-17.93) IU/L，P0.05；T3AST：MD為-5.85IU/L，95%CI為(-29.14,17.45) IU/L，P=0.62；T4ALT：MD為-2.32IU/L，，95%CI為(-7.29,2.65) IU/L，P=0.36。 結論：丙泊酚對肝門阻斷肝切除術的肝缺血再灌注損傷有一定的保護作用。
[Abstract]:Objective: to evaluate the protective effect of propofol on hepatic ischemia reperfusion injury by Meta analysis. Methods: according to the retrieval strategy, Pub Med,EMBASE,Web of Knowledge,TheCochane Library, Chinese Biomedical Literature Database, Wanfang Full-text Database, Weipu Chinese Sci-tech Journals Database, Chinese Journal of Science and Technology, China knowledge Network were searched. The retrieval date was as of February 28, 2014. Limited to Chinese and English languages, and computer or manual reference cited in the study. All randomized controlled trials to study the effects of propofol anesthesia on hepatic ischemia-reperfusion in adult patients undergoing hepatectomy with hilar occlusion were included in accordance with established inclusion and exclusion criteria. RevMan5.2 software was used to analyze more than 2 related articles in Meta. Results: a total of 21 articles, including 686 cases in the experimental group and 511 cases in the control group, were found. Main outcome measures: end of hilar occlusion to reopening 15min (T1) SOD,MDA,ALT,AST, 30-45min (T2) SOD,MDA. 鏈悗絎

本文編號：2288851